APGE
Apogee Therapeutics, Inc. Common Stock
NASDAQ: APGE · HEALTHCARE · BIOTECHNOLOGY
$82.03
-3.91% today
Updated 2026-04-29
Market cap
$6.39B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.22
Dividend yield
—
52W range
$34 – $95
Volume
0.9M
Apogee Therapeutics, Inc. Common Stock (APGE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | — | — | $189000.00 | $1.42M |
| Gross profit | — | — | $-189000.00 | $-1.42M |
| Gross margin | — | — | — | — |
| R&D | $27.79M | $68.42M | $167.87M | $214.71M |
| SG&A | $2.94M | $24.58M | $49.01M | $70.88M |
| Operating income | $-30.73M | $-93.00M | $-216.87M | $-285.60M |
| Operating margin | — | — | — | — |
| EBITDA | $-39.78M | $-74.97M | $-216.68M | $-284.18M |
| EBITDA margin | — | — | — | — |
| EBIT | $-64.25M | $-83.98M | $-216.87M | $-285.60M |
| Interest expense | $9.15M | $0.00 | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-39.78M | $-83.98M | $-182.15M | $-255.84M |
| Net income growth (YoY) | — | -111.1% | -116.9% | -40.5% |
| Profit margin | — | — | — | — |